Overview
- Bio Protocol unveiled OpenLabs at DeSci. Berlin as a single environment where AI-assisted tools, collaboration features, and on‑chain funding are combined to move ideas toward funded research.
- The system embeds community governance so BIO token holders can vote on which projects receive funding and influence project development inside the platform.
- Bio Protocol said its BIO Genesis initiative has raised more than $33 million to support projects in the OpenLabs ecosystem.
- The launch highlighted two flagship use cases, RheumaAI for rheumatology research and PeptAI for peptide discovery, as early demonstrations of the workflow.
- Analysts and reporters flagged mixed short‑term market signals for the BIO token and unresolved legal risks around tokenized biotech intellectual property as the biggest near‑term questions to watch.